IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report.
Humans
Male
Aged
Carboplatin
/ adverse effects
Paclitaxel
/ adverse effects
Antibodies, Monoclonal, Humanized
/ adverse effects
Lung Neoplasms
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carcinoma, Squamous Cell
/ drug therapy
Albumins
/ adverse effects
IgA Vasculitis
/ chemically induced
Immunoglobulin A
Immune Checkpoint Inhibitors
/ adverse effects
IgA vasculitis
immune checkpoint inhibitor
immune-related adverse event
non-small-cell lung cancer
pembrolizumab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
15
01
2024
accepted:
30
07
2024
medline:
1
9
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
A 73-year-old man with lung squamous cell carcinoma was administered carboplatin + nab-paclitaxel + pembrolizumab for four cycles. Subsequently, he presented with multiple purpuras on his extremities, joint swelling on his fingers, abdominal pain, and diarrhea, accompanied by acute kidney injury (AKI), increased proteinuria, hematuria, and elevated C-reactive protein levels. Skin biopsy showed leukocytoclastic vasculitis as well as IgA and C3 deposition in the vessel walls. Based on these findings, the patient was diagnosed with IgA vasculitis as an immune-related adverse event (irAE) induced by carboplatin + nab-paclitaxel + pembrolizumab. After discontinuation of pembrolizumab and glucocorticoids, the symptoms immediately resolved. Regular monitoring of skin, blood tests, and urinalysis are necessary, and the possibility of irAE IgA vasculitis should be considered in cases of purpura and AKI during treatment with immune checkpoint inhibitors.
Identifiants
pubmed: 39206190
doi: 10.3389/fimmu.2024.1370972
pmc: PMC11349625
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Antibodies, Monoclonal, Humanized
0
pembrolizumab
DPT0O3T46P
130-nm albumin-bound paclitaxel
0
Albumins
0
Immunoglobulin A
0
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1370972Informations de copyright
Copyright © 2024 Terashima, Matsumoto, Ozaki, Nakagawa, Nakagome, Terasaki, Iida, Mitsugi, Kuramochi, Okada, Inoue, Matsuki, Kitagawa, Fukuizumi, Onda, Takeuchi, Miyanaga, Kasahara and Seike.
Déclaration de conflit d'intérêts
AM has received honoraria from AstraZeneca, Nippon Kayaku, Merck, Kyowa Kirin, and Pfizer. KK has received honoraria Chugai Pharmaceutical, Eli Lilly, and Bristol-Myers Squibb. MS has received grants and contracts from any entity from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Nippon Boehringer Ingelheim, Nippon Kayaku, and Kyowa Hakko Kirin; honoraria from AstraZeneca, MSD K.K, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku, Daiichi-Sankyo Company, Merck Biopharma, and Amgen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.